Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JunB shRNA is a gene-silencing therapeutic candidate primarily utilized in preclinical research to investigate the role of the AP-1 transcription factor JunB in multiple myeloma (MM). Delivered via viral vectors such as pLKO.1 or inducible Tet-systems, this short hairpin RNA (shRNA) specifically targets and reduces the expression of JunB. In the bone marrow microenvironment, JunB is induced by soluble factors like IL-6 and promotes MM cell proliferation, survival, and resistance to standard therapies like dexamethasone and bortezomib. By knocking down JunB, the expression of downstream pro-survival targets such as Mcl-1 and c-Myc is downregulated, leading to inhibited tumor growth and sensitized cancer cells to chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JunB shRNA.